[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-001", "question": "A 45-year-old man with a history of migraine presents with acute onset of right-sided hemiparesis and aphasia. MRI shows restricted diffusion in the left middle cerebral artery territory, but no large vessel occlusion on angiography. Lumbar puncture reveals normal opening pressure, 5 WBCs/μL (all lymphocytes), protein 45 mg/dL, glucose 60 mg/dL, and negative oligoclonal bands. Serum testing is positive for anti-NMDA receptor antibodies. What is the most appropriate next step in management?", "options": ["Initiate intravenous thrombolysis", "Administer high-dose intravenous methylprednisolone", "Start rituximab infusion", "Perform plasmapheresis", "Administer acyclovir empirically"], "answer": "C", "answer_index": 2, "explanation": "The presentation suggests anti-NMDA receptor encephalitis mimicking stroke, and rituximab is indicated for refractory cases or as first-line in severe presentations per subspecialty guidelines. High-dose steroids are often initial, but in antibody-positive cases with stroke-like features, rituximab targets B-cell depletion more effectively. Plasmapheresis is an alternative but not superior in this context without evidence of fulminant progression.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: acute stroke-like presentation (hemiparesis, aphasia, diffusion restriction) with positive anti-NMDA receptor antibodies in CSF/serum, normal angiography, and mildly inflammatory CSF. This defines anti-NMDA receptor encephalitis. Main logical issue: A unique best answer exists, but the provided key (C, rituximab) is not it. For acute management of confirmed anti-NMDA receptor encephalitis, first-line immunotherapy is high-dose intravenous corticosteroids (B) and/or IVIG/plasmapheresis (D), not rituximab as initial step. Rituximab is a second-line or adjunctive agent. Main medical accuracy issue: The rationale incorrectly prioritizes rituximab over first-line immunotherapies. Minimal fix: Change the key to B (high-dose intravenous methylprednisolone) and adjust the rationale to reflect standard first-line immunotherapy sequencing.\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1021)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-002", "question": "A 62-year-old woman with Parkinson's disease on levodopa/carbidopa develops sudden visual hallucinations and paranoia. She has no fever, normal vital signs, and her Unified Parkinson's Disease Rating Scale score has worsened by 15 points. CSF analysis shows 10 WBCs/μL (mononuclear), protein 55 mg/dL, and negative PCR for herpes simplex virus. What is the most likely underlying mechanism?", "options": ["Dopaminergic overstimulation in mesolimbic pathways", "Alpha-synuclein aggregation in occipital lobes", "Autoimmune encephalitis with anti-LGI1 antibodies", "Lewy body deposition in limbic structures", "Serotonergic imbalance from medication withdrawal"], "answer": "C", "answer_index": 2, "explanation": "This scenario points to anti-LGI1 encephalitis, which can mimic psychiatric decompensation in Parkinson's patients and is associated with faciobrachial dystonic seizures or hallucinations. Dopaminergic effects are common but do not explain the CSF pleocytosis. Lewy body involvement is typical in dementia with Lewy bodies but lacks the acute inflammatory CSF findings here.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: Parkinson's patient on levodopa, acute hallucinations/paranoia, worsened UPDRS, CSF with mild lymphocytic pleocytosis and elevated protein, negative HSV PCR. The most likely mechanism is dopaminergic overstimulation (A), a well-known adverse effect of levodopa causing psychosis, especially with dose escalation or disease progression. The CSF findings are nonspecific and mild; they do not definitively point to autoimmune encephalitis over other causes. The keyed answer (C) requires assuming the CSF changes are diagnostic of anti-LGI1, which is not supported without specific antibody testing or typical features like faciobrachial dystonic seizures. Alternatives B and D are chronic processes not explaining acute decompensation. E is not supported. Main logical issue: A unique best answer exists (A), but the provided key (C) is not it. Medical accuracy issue: Overinterpreting mild CSF abnormalities as specific for autoimmune encephalitis. Minimal fix: Change key to A and adjust rationale to acknowledge that mild CSF pleocytosis can occur in drug-induced psychosis or other conditions, not exclusively autoimmune encephalitis.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \t\n  \"3\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: Parkinson's patient on levodopa, acute hallucinations/paranoia, worsened UPDRS, CSF with mild lymphocytic pleocytosis and elevated protein, negative HSV PCR. The most likely mechanism is dopaminergic overstimulation (A), a well-known adverse effect of levodopa causing psychosis, especially with dose escalation or disease progression. The CSF findings are nonspecific and mild; they do not definitively point to autoimmune encephalitis over other causes. The keyed answer (C) requires assuming the CSF changes are diagnostic of anti-LGI1, which is not supported without specific antibody testing or typical features like faciobrachial dystonic seizures. Alternatives B and D are chronic processes not explaining acute decompensation. E is not supported. Main logical issue: A unique best answer exists (A), but the provided key (C) is not it. Medical accuracy issue: Overinterpreting mild CSF abnormalities as specific for autoimmune encephalitis. Minimal fix: Change key to A and adjust rationale to acknowledge that mild CSF pleocytosis can occur in drug-induced psychosis or other conditions, not exclusively autoimmune encephalitis.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-003", "question": "A 28-year-old woman at 32 weeks gestation presents with severe pelvic pain and vaginal bleeding. Ultrasound shows a low-lying placenta with abnormal lacunae and loss of the retroplacental clear space. MRI confirms myometrial thinning and turbulent flow voids. What is the most appropriate management strategy?", "options": ["Expectant management with bed rest", "Immediate cesarean delivery", "Uterine artery embolization", "Balloon tamponade post-delivery", "Prophylactic internal iliac artery ligation"], "answer": "E", "answer_index": 4, "explanation": "This describes placenta accreta spectrum, and prophylactic internal iliac artery ligation reduces hemorrhage risk during planned cesarean hysterectomy in high-risk cases. Immediate delivery risks uncontrolled bleeding without preparation. Embolization is adjunctive but not primary in antenatal planning for accreta.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: 32 weeks gestation, severe pain/bleeding, ultrasound/MRI findings diagnostic of placenta accreta spectrum (abnormal lacunae, loss of retroplacental clear space, myometrial thinning, flow voids). The most appropriate management for a stable patient with a known accreta at 32 weeks is planned, multidisciplinary delivery (often at 34-36 weeks) with cesarean hysterectomy, not immediate delivery. Prophylactic internal iliac artery ligation (E) is an outdated and rarely used technique; current standard is preoperative planning, which may include ureteric stents, cell salvage, and availability of interventional radiology for potential embolization. The keyed answer is not the modern best practice. Immediate cesarean delivery (B) is incorrect for a stable patient, but the provided key (E) is also not the standard primary strategy. Minimal fix: Change key to 'B' and revise rationale to emphasize that for an unstable patient with active bleeding, immediate delivery is indicated, but for a stable patient, the stem should specify stability to make planned delivery the best answer.\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":  \"2\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: 32 weeks gestation, severe pain/bleeding, ultrasound/MRI findings diagnostic of placenta accreta spectrum (abnormal lacunae, loss of retroplacental clear space, myometrial thinning, flow voids). The most appropriate management for a stable patient with a known accreta at 32 weeks is planned, multidisciplinary delivery (often at 34-36 weeks) with cesarean hysterectomy, not immediate delivery. Prophylactic internal iliac artery ligation (E) is an outdated and rarely used technique; current standard is preoperative planning, which may include ureteric stents, cell salvage, and availability of interventional radiology for potential embolization. The keyed answer is not the modern best practice. Immediate cesarean delivery (B) is incorrect for a stable patient, but the provided key (E) is also not the standard primary strategy. Minimal fix: Change key to 'B' and revise rationale to emphasize that for an unstable patient with active bleeding, immediate delivery is indicated, but for a stable patient, the stem should specify stability to make planned delivery the best answer.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-004", "question": "A 35-year-old woman with endometriosis undergoes laparoscopic excision and develops postoperative fever, leukocytosis, and pelvic pain. CT shows a 5 cm complex adnexal mass with gas bubbles. Blood cultures are negative, but vaginal cultures grow mixed anaerobes. What is the most likely diagnosis?", "options": ["Ovarian abscess from bowel perforation", "Endometrioma superinfection", "Tubo-ovarian abscess from pelvic inflammatory disease", "Postoperative hematoma with secondary infection", "Clostridial myonecrosis of the uterus"], "answer": "A", "answer_index": 0, "explanation": "Bowel perforation during endometriosis surgery can lead to ovarian abscess with gas-forming anaerobes, explaining the imaging and cultures. Endometrioma infection is less likely without prior instrumentation. Tubo-ovarian abscess typically involves gonadal pathogens, not mixed anaerobes from bowel flora.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: Postoperative fever, leukocytosis, pelvic pain, CT showing a 5 cm complex adnexal mass with gas bubbles, and vaginal cultures growing mixed anaerobes. The presence of gas strongly suggests a gas-forming infection, and the postoperative context points to a surgical complication. Main logical issue: The keyed answer (A, ovarian abscess from bowel perforation) is not the single best answer. Option D (postoperative hematoma with secondary infection) is equally defensible given the postoperative setting, complex mass, and mixed anaerobic flora from the vagina, which could seed a hematoma. A unique best answer requires an unstated assumption that gas bubbles definitively indicate bowel perforation over infection of a hematoma. Main medical accuracy issue: Minor. Both A and D are plausible, but the item incorrectly presents A as uniquely best. Minimal fix: Add a stem detail like 'CT shows a mass contiguous with a bowel wall defect' to favor A, or 'CT shows a mass with an air-fluid level and no direct bowel communication' to favor D.\",\n    \"logical_false_reason\": \"M\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1221)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-005", "question": "A 58-year-old man with hypertrophic cardiomyopathy presents with syncope. Echocardiogram shows left ventricular outflow tract gradient of 80 mmHg at rest, increasing to 120 mmHg with Valsalva. He is on beta-blockers but remains symptomatic. Genetic testing reveals a MYH7 mutation. What is the most appropriate next intervention?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantable cardioverter-defibrillator placement", "Dual-chamber pacing", "Mavacamten therapy"], "answer": "E", "answer_index": 4, "explanation": "Mavacamten, a cardiac myosin inhibitor, is indicated for symptomatic obstructive hypertrophic cardiomyopathy refractory to beta-blockers, targeting the underlying MYH7-related hypercontractility. Alcohol ablation and myectomy are invasive options for severe cases, but mavacamten offers medical management first. ICD is for arrhythmia risk, not outflow obstruction.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: symptomatic obstructive HCM (LVOT gradient 80 mmHg at rest, increasing to 120 mmHg) refractory to beta-blockers, with a known MYH7 mutation. The most appropriate next intervention per major guidelines (ACC/AHA) for drug-refractory, severely symptomatic obstructive HCM is invasive septal reduction therapy (surgical myectomy or, in select cases, alcohol septal ablation). Mavacamten is a newer medical therapy, but current guidelines position it as an option for patients who are not candidates for or decline septal reduction therapy, not as the definitive 'most appropriate next intervention' over proven invasive therapies in this severe, refractory case. Main logical issue: The keyed answer (E) is not the single best, guideline-supported next step. Minimal fix: Change the key to B (Surgical myectomy) and adjust the rationale to reflect guideline-based prioritization of septal reduction therapy for severe, refractory obstructive HCM.\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":  \"3\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: symptomatic obstructive HCM (LVOT gradient 80 mmHg at rest, increasing to 120 mmHg) refractory to beta-blockers, with a known MYH7 mutation. The most appropriate next intervention per major guidelines (ACC/AHA) for drug-refractory, severely symptomatic obstructive HCM is invasive septal reduction therapy (surgical myectomy or, in select cases, alcohol septal ablation). Mavacamten is a newer medical therapy, but current guidelines position it as an option for patients who are not candidates for or decline septal reduction therapy, not as the definitive 'most appropriate next intervention' over proven invasive therapies in this severe, refractory case. Main logical issue: The keyed answer (E) is not the single best, guideline-supported next step. Minimal fix: Change the key to B (Surgical myectomy) and adjust the rationale to reflect guideline-based prioritization of septal reduction therapy for severe, refractory obstructive HCM.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-006", "question": "A 70-year-old woman with atrial fibrillation on apixaban develops acute chest pain. Coronary angiography shows spontaneous coronary artery dissection in the left anterior descending artery. She is hemodynamically stable with TIMI 3 flow. What is the most appropriate management?", "options": ["Percutaneous coronary intervention with stenting", "Continuation of apixaban with close monitoring", "Switch to dual antiplatelet therapy", "Surgical bypass grafting", "Conservative management with beta-blockers"], "answer": "E", "answer_index": 4, "explanation": "Conservative management with beta-blockers is preferred for stable spontaneous coronary artery dissection with preserved flow, as it promotes healing and reduces shear stress. Anticoagulation like apixaban increases bleeding risk in dissection. PCI is reserved for unstable cases due to high complication rates.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: Spontaneous coronary artery dissection (SCAD) in a stable patient (hemodynamically stable, TIMI 3 flow) on a direct oral anticoagulant (apixaban). The standard of care for stable SCAD is conservative management, which includes stopping anticoagulation and initiating antiplatelet therapy, often dual antiplatelet therapy (DAPT), to promote healing and prevent thrombosis. Beta-blockers are a supportive component but not the sole management. The keyed answer (E) is incomplete and incorrect as the sole best choice. Option C (Switch to dual antiplatelet therapy) is the most appropriate single best answer, as it directly addresses the need to stop anticoagulation and initiate standard medical therapy. Main logical issue: The key does not match the single best answer. Minimal fix: Change the key to C and update the rationale to reflect that DAPT is the cornerstone of medical management for stable SCAD, with beta-blockers as an adjunct.\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1121)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-007", "question": "A 40-year-old man returning from West Africa presents with fever, myalgias, and petechial rash. Labs show thrombocytopenia, elevated liver enzymes, and PCR positive for Lassa virus. He develops acute kidney injury with oliguria. What is the most appropriate therapeutic intervention?", "options": ["Intravenous ribavirin", "Supportive care with hemodialysis", "Convalescent plasma transfusion", "Favipiravir administration", "Monoclonal antibody therapy"], "answer": "A", "answer_index": 0, "explanation": "Intravenous ribavirin is the mainstay for Lassa fever, reducing mortality especially when initiated early, and it addresses viremia in cases with renal involvement. Supportive care is essential but not sufficient alone. Favipiravir is investigational and not standard for Lassa.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Lassa virus PCR positivity, acute kidney injury with oliguria. The question asks for the most appropriate therapeutic intervention for confirmed Lassa fever with renal complications. Intravenous ribavirin is the standard antiviral for Lassa fever, supported by guidelines and evidence for reducing mortality, especially in severe cases. The alternatives are inferior: B (supportive hemodialysis) is a component of care but not the primary therapeutic intervention; C (convalescent plasma) has limited evidence and is not standard; D (favipiravir) is investigational; E (monoclonal antibodies) are not approved for Lassa. No logical contradictions or underspecification exist. Medical accuracy is sound. Minimal fix: None required; the item is clear and accurate.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 950)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-008", "question": "A 55-year-old immunocompromised patient with lung transplant develops dyspnea and ground-glass opacities on CT. Bronchoalveolar lavage PCR is positive for Pneumocystis jirovecii, but serum beta-D-glucan is negative. He is on trimethoprim-sulfamethoxazole prophylaxis. What explains the breakthrough infection?", "options": ["Dihydropteroate synthase gene mutation", "Non-adherence to prophylaxis", "Concurrent cytomegalovirus co-infection", "Inadequate dosing in obesity", "Atovaquone cross-resistance"], "answer": "A", "answer_index": 0, "explanation": "Mutations in the dihydropteroate synthase gene confer resistance to sulfamethoxazole in Pneumocystis, leading to breakthrough despite prophylaxis in immunocompromised hosts. Non-adherence is common but less likely with negative beta-D-glucan suggesting low burden. CMV co-infection exacerbates but does not cause resistance.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: U (Underspecified). Verdict: Not uniquely determinable. Key stem clues: immunocompromised lung transplant patient on TMP-SMX prophylaxis with PJP breakthrough infection and negative serum beta-D-glucan. The negative beta-D-glucan is a critical but ambiguous detail; it is not a reliable marker of fungal burden or adherence in this context, and its inclusion does not logically exclude non-adherence (B) or support a genetic mutation (A) over other options. Main logical issue: The stem is underspecified. The negative beta-D-glucan is presented as a discriminator but does not provide a clear, unique path to the keyed answer (A) without assuming it indicates a low organism burden, which is not a definitive association. Options D (inadequate dosing) and B remain plausible without additional data on weight or adherence history. Main medical accuracy issue: The association between a negative beta-D-glucan and a low fungal burden in PJP is not reliable for ruling out non-adherence or confirming resistance. Minimal fix: Remove the ambiguous beta-D-glucan result and specify confirmed prophylaxis adherence and appropriate weight-based dosing to make genetic resistance (A) the clear best answer.\",\n  \"logical_false_reason\": \"U\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \t\n  \"3\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified). Verdict: Not uniquely determinable. Key stem clues: immunocompromised lung transplant patient on TMP-SMX prophylaxis with PJP breakthrough infection and negative serum beta-D-glucan. The negative beta-D-glucan is a critical but ambiguous detail; it is not a reliable marker of fungal burden or adherence in this context, and its inclusion does not logically exclude non-adherence (B) or support a genetic mutation (A) over other options. Main logical issue: The stem is underspecified. The negative beta-D-glucan is presented as a discriminator but does not provide a clear, unique path to the keyed answer (A) without assuming it indicates a low organism burden, which is not a definitive association. Options D (inadequate dosing) and B remain plausible without additional data on weight or adherence history. Main medical accuracy issue: The association between a negative beta-D-glucan and a low fungal burden in PJP is not reliable for ruling out non-adherence or confirming resistance. Minimal fix: Remove the ambiguous beta-D-glucan result and specify confirmed prophylaxis adherence and appropriate weight-based dosing to make genetic resistance (A) the clear best answer.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-009", "question": "A 50-year-old woman with rheumatoid arthritis on tofacitinib presents with symmetric polyarthritis flare, fever, and macular rash. Labs show pancytopenia, ferritin 10,000 ng/mL, triglycerides 400 mg/dL, and fibrinogen 100 mg/dL. Bone marrow biopsy reveals hemophagocytosis. What is the most appropriate initial treatment?", "options": ["High-dose glucocorticoids", "Cyclosporine A", "Anakinra", "Etoposide-based chemotherapy", "Intravenous immunoglobulin"], "answer": "C", "answer_index": 2, "explanation": "Anakinra, an IL-1 inhibitor, is effective for macrophage activation syndrome in rheumatoid arthritis, targeting cytokine storm and improving survival without broad immunosuppression. Glucocorticoids are adjunctive but insufficient alone in JAK inhibitor-associated cases. Etoposide is for refractory HLH but not first-line here.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: Rheumatoid arthritis on tofacitinib, fever, pancytopenia, hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia, hemophagocytosis on bone marrow—all diagnostic for secondary hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS). The most appropriate initial treatment for secondary HLH/MAS, per current guidelines (HLH-94/2004, ACR/EULAR), is high-dose glucocorticoids (often with anakinra added, but steroids are first-line). Anakinra (C) is a valid early agent, especially in rheumatologic MAS, but is not universally accepted as the sole initial treatment over steroids. Option A (high-dose glucocorticoids) is equally or more defensible as first-line, making the key not uniquely best. Main logical issue: Miskeying—a unique best answer exists (A or C), but the provided key (C) is not clearly superior. Minimal fix: Change key to A or revise stem to specify \\\"refractory to high-dose glucocorticoids\\\" to justify C as initial.\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1141)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-010", "question": "A 65-year-old man with giant cell arteritis on prednisone taper develops jaw claudication and vision loss. ESR is 80 mm/hr, and temporal artery biopsy is negative. CTA shows aortic arch involvement. What is the most appropriate escalation in therapy?", "options": ["Increase prednisone to 60 mg daily", "Add methotrexate", "Initiate tocilizumab", "Start cyclophosphamide", "Perform temporal artery ultrasound"], "answer": "C", "answer_index": 2, "explanation": "Tocilizumab, an IL-6 inhibitor, is indicated for refractory giant cell arteritis with large vessel involvement, reducing relapse and steroid requirements. High-dose prednisone is initial but inadequate for escalation in biopsy-negative cases. Methotrexate is steroid-sparing but less effective for vision-threatening disease.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: Giant cell arteritis (GCA) with jaw claudication and vision loss (high-risk features), negative temporal artery biopsy, CTA showing aortic arch involvement (large-vessel GCA), and patient already on a prednisone taper with disease progression. This defines refractory GCA with large-vessel involvement. The keyed answer (C, tocilizumab) aligns with current guidelines (e.g., GiACTA trial) for refractory or relapsing GCA, especially with large-vessel disease, to reduce steroid use and prevent relapse. Alternatives are inferior: A (high-dose prednisone) is failing; B (methotrexate) is a steroid-sparer but less effective for vision-threatening or refractory cases; D (cyclophosphamide) is reserved for severe, life-threatening vasculitis; E (ultrasound) is diagnostic, not therapeutic escalation. No logical contradictions or missing critical details. Medical accuracy is sound. Minimal fix: None required; item is clear and accurate.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1108)"}]